Adcytherix focuses on designing and developing highly selective antibody-drug conjugates that incorporate proprietary payloads aimed at improving efficacy, tolerability, and resistance profiles in oncology. Its lead candidate, ADCX-020, is progressing toward first-in-human studies, with IND and CTA filings targeted for the end of 2025. In parallel, the company is expanding a broader pipeline of differentiated ADCs that leverage its novel payload platform. Founded about 18 months ago and led by CEO and founder Jack Elands, the team draws on deep scientific and commercial expertise in the ADC field. The company positions itself as a European leader in next-generation ADC innovation, emphasizing precision targeting and payload differentiation. With the recent €105 million Series A financing, Adcytherix now has substantial resources to transition from preclinical research to clinical development. The new capital underpins both the advancement of ADCX-020 and the ongoing build-out of its proprietary ADC platform.

Total raised

$154M

Funding rounds

2

Latest round

Series A

Latest activity

Oct 2025